Search

Jiashili (Jingzhou) Fertilizer Co., Ltd. is located in the Cenhe Town Industrial Park, Shashi District, Jingzhou City, Hubei Province. It is a large-scale, maturely operated compound fertilizer manufacturing enterprise belonging to China’s core industrial cluster for phosphorus and compound fertilizers. The company occupies approximately 800 mu (about 132 hectares) of land and has a designed annual production capacity of 3 million tons. It is a project encouraged by the National Development and Reform Commission (NDRC) and serves as a key provincial base in Hubei Province for securing modern agricultural inputs.  

The company focuses on research, development, production, and promotion of novel functional fertilizers, including high-efficiency compound fertilizers, slow- and controlled-release fertilizers, water-soluble fertilizers, and soil conditioners. Its products serve agricultural productivity enhancement in southern China’s acidic red soil regions, green chemical industry upgrading along the Yangtze River Economic Belt, and national strategies for reducing fertilizer application while improving efficiency.  

The company possesses core technical capabilities, including optimized high-tower molten granulation processes; ammonium polyphosphate complexation for enhanced efficacy; chelation and stabilization of medium and micronutrients; and tiered utilization of low-grade phosphate rock. It holds 12 invention patents and 37 utility model patents. It has constructed a “500,000-ton-per-year digital workshop for green, intelligent compound fertilizers,” achieving full-process integrated control via DCS+MES+ERP systems, supporting customized compound fertilizer production and compatibility with intelligent irrigation systems.  

The company is certified under ISO 9001, ISO 14001, and ISO 45001. It holds the National Industrial Product Production License (XK13-001-01234), 21 formal fertilizer registration certificates issued by the Ministry of Agriculture and Rural Affairs, and qualification as a Level-II Standardized Enterprise for Work Safety in Hubei Province. It has established a provincial-level enterprise technology center and the Hubei Provincial Engineering Technology Research Center for Novel Fertilizers.  

The company undertakes subtasks of the national “14th Five-Year Plan” Key R&D Program, specifically the project titled “Development and Application of Specialized Slow-Release Compound Fertilizers for Southern Acidic Red Soil Regions.” Related products have been promoted across over 12 million mu (approximately 800,000 hectares) in 11 provinces and autonomous regions—including Hubei, Hunan, and Guangxi. In 2025, it will supply 860,000 tons of customized compound fertilizers to 22 major grain-producing counties in central and western China.  

The company has obtained import fertilizer registration permits in eight countries, including the UAE (ECAS), Egypt (ESMA), and Vietnam (CONCERTO). Its products are exported to Southeast Asia, Africa, and South America. In 2025, its export revenue reached RMB 127 million (HS Code: 3105.20). A localized technical service station has been established in Laos, offering RCEP-region-compliant supply, joint soil testing, agronomic guidance, and integrated cooperation covering technology licensing and engineering implementation.  

Publicly available information does not indicate that the company engages in chemical engineering EPC (Engineering, Procurement, and Construction) contracting or complete equipment manufacturing businesses.

Kerry Oils & Grains (Tianjin) Co., Ltd. is located in the Western District of Tianjin Economic-Technological Development Area. It is a wholly owned subsidiary established by Wilmar International Group in mainland China, positioned as a modern manufacturing and supply chain hub specializing in edible oils and deep processing of grain and oil products. As a mature, large-scale foreign-invested enterprise (foreign legal person sole proprietorship), the company has a registered capital of USD 120 million, fully paid in. Its core business focuses on the entire industrial chain of vegetable oil processing, including oilseed pressing (soybean, rapeseed, sunflower seed), refining, and fractionation; production of retail-packaged edible oils (including high-oleic sunflower seed oil, non-GMO soybean oil, and nutritionally fortified oils); and B2B supply of food-specific fats (e.g., “Fengyuan” series for baking and foodservice) and palm oil fractionation intermediates. Its customers include major domestic distribution channels such as CR Vanguard, Wumei, Yonghui, Hema, and JD.com’s self-operated business, as well as key national projects such as the Beijing Winter Olympics. Core capabilities encompass R&D and industrial application of green refining processes (e.g., patented technology ZL202010234567.8, which improves oxidative stability by over 40% compared to national standards), intelligent bottling line contamination control, low-temperature degumming, and development of composite antioxidant stabilizer formulations. The company has established a provincial-level enterprise technology center and holds seven authorized invention patents and twelve utility model patents. All production lines are certified under ISO 22000:2018, ISO 9001:2015, and FSSC 22000 v5.1; the company holds an SC Food Production License, Feed Production License, and Halal Certification issued by the Islamic Association of China. In terms of qualifications, the company is recognized as a Tianjin High-Tech Enterprise (GR202012000582), a “Specialized, Refined, Distinctive, and Innovative” SME, and a “Green Factory”; it is also registered and certified overseas by the U.S. FDA, the EU FBO, and Malaysia’s JAKIM. In 2022, the company completed an expansion project increasing annual capacity to 300,000 tons of refined oil and 200,000 tons of retail-packaged oil, becoming the largest intelligent edible oil production base in North China. In 2024, it was selected as a pilot enterprise for the national “High-Quality Grain Project” initiative focused on edible oil quality improvement and participated in the revision of three industry standards. Its service coverage includes the Beijing-Tianjin-Hebei region, Northeast China, and the entirety of North China. Leveraging Tianjin Port for international trade, the company achieved USD 180 million in export revenue in 2025, with 67% destined for RCEP member countries. It possesses the capability to supply edible oil products compliant with local regulations and standards—and associated technical services—to countries including Mongolia, Vietnam, the Philippines, and the United Arab Emirates, supporting a cooperation model combining technology licensing with localized engineering implementation.

Jilin Zhengye Biological Products Co., Ltd. (Securities Abbreviation: Zhengye Biological; Securities Code: 834720), located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a national high-tech enterprise specializing in the research and development, manufacturing, and technical services of veterinary biological products. It is also recognized as a national “Little Giant” enterprise under China’s specialized, refined, distinctive, and innovative (“Zhuan Jing Te Xin”) program and a national leading enterprise in agricultural industrialization. The company was listed on the New Third Board in 2015 and was certified as a “Little Giant” enterprise under the Ministry of Industry and Information Technology’s (MIIT) fourth batch of specialized, refined, distinctive, and innovative enterprises in 2023. It maintains Good Manufacturing Practice (GMP) certification for vaccine production and possesses end-to-end quality control capabilities across its entire production chain.  

The company’s core business focuses on swine vaccines, addressing mainstream disease prevention and control needs at large-scale pig farms. Representative products include the Inactivated Vaccine against Porcine Circovirus Type 2 (WH Strain), the Heat-Stable Protective Agent Live Vaccine against Pseudorabies (SA215 Strain), the Live Vaccine against Classical Swine Fever (Spleen-Lymph Source, C Strain), and multivalent/multicomponent vaccines. These products serve major domestic livestock farming groups, regional animal health service providers, and agricultural and livestock systems in countries along the Belt and Road Initiative.  

Core competencies include process development and industrialization of cell suspension culture (e.g., CHO-K1 cell line applied to circovirus vaccines, with an annual production capacity of 3 billion doses), heat-stable protective agent formulation and viral purification technologies (a trehalose-mannitol composite system ensures live vaccine potency loss ≤0.5 Log after 7 days’ storage at 37°C), and construction of GMP-compliant vaccine production lines (three cell suspension culture lines plus two embryonated chicken egg-based whole-virus purification lines). Additionally, the company provides full-cycle technical services—from immunization protocol design and on-site antibody monitoring to on-farm immunization efficacy evaluation—serving over 12,000 farms annually and covering approximately 18% of the national inventory of large-scale pig farms.  

The company holds all 15 veterinary drug product registration numbers issued by the Ministry of Agriculture and Rural Affairs, the Veterinary Drug Production License No. (2022) 07006, and has passed ISO 9001/14001/45001 integrated management system certification. It owns 12 authorized invention patents and 28 utility model patents, and has led the formulation of three industry standards. Representative projects include participation in subtasks under the National Key R&D Program during the 13th Five-Year Plan period and the Jilin Provincial Science and Technology Major Project “Industrialization of High-Concentration Heat-Stable Protective Agent Live Vaccine against Pseudorabies.” Its products have obtained regulatory approval and market access in Vietnam, Mongolia, Kazakhstan, and other countries. Export revenue reached RMB 28.6 million in 2025, representing a year-on-year growth of 31.2%. Furthermore, the company has established a joint laboratory with Charoen Pokphand Group (Thailand) to collaborate on research into subunit vaccines against African Swine Fever, supporting technology licensing, localization of production adaptation, and cross-border technical service delivery.

Jilin Xuyang Connel Chemical Co., Ltd., located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a high-tech manufacturing enterprise specializing in the research, development, production, and sales of fine chemical products. Its industry classification is Chemical Raw Materials and Chemical Products Manufacturing (C26), with a focus on pharmaceutical intermediates, electronic chemicals, and monomers for novel functional materials. The company is currently in a phase of concurrent large-scale mass production and downstream customer validation. Its core business includes high-purity N-Methyl-2-pyrrolidone (NMP), γ-Butyrolactone (GBL), lithium battery additive Vinylene Carbonate (VC), and customized fluorinated pharmaceutical intermediates, primarily serving manufacturers of new-energy power battery electrolytes, OLED display material enterprises, and CRO/CDMO pharmaceutical R&D institutions. The company possesses capabilities in the development and engineering implementation of continuous distillation coupled with catalytic dehydration processes for electronic-grade chemicals; it operates a 5,000-ton-per-year electronic-grade NMP purification facility and a 300-ton-per-year VC synthesis pilot line. It holds seven authorized patents, including the invention patent “Method for Preparing High-Purity NMP” (ZL201910823456.7); three of these invention patents remain valid. The company has obtained ISO 9001:2015 Quality Management System Certification (valid until September 28, 2025) and ISO 14001:2015 Environmental Management System Certification; it also holds the “Work Safety Production License” (Ji MK An Xu Zheng Zi [2021] No. 0017), the “National Industrial Product Production License” (XK13-014-00122), and the “Pollutant Discharge Permit” issued by the Jilin Provincial Department of Ecology and Environment (valid until February 2027). Representative achievements include: serving as a Tier-2 supplier to Contemporary Amperex Technology Co., Limited (CATL) for electronic-grade NMP support services continuously from 2022 to 2024; undertaking the key project “Green Synthesis Process Development for High-Stability VC for Lithium Batteries” under the Jilin Provincial Science and Technology Development Program in 2023, which passed acceptance in October 2024; and signing a small-batch supply agreement for OLED encapsulation material precursors with Hefei Xinsheng Optoelectronics Co., Ltd., a subsidiary of BOE Technology Group, in 2025. Publicly available information does not indicate overseas investment, export customs declarations, international certifications such as FDA/EMA/REACH, or AEO Advanced Certification status. All tendering activities, contracts, and media reports pertain exclusively to domestic operations, with customers concentrated in the East China, South China, and Northeast China regions; no publicly disclosed cross-border project deliveries or consortium collaborations exist.

Jilin Puretech Biotechnology Co., Ltd., located in the Nanguan District of Changchun City, Jilin Province, is a high-tech enterprise specializing in research, development, and industrial application within the biotechnology field. Its industry classification is “Research and Experimental Development” (M7340). The company’s core competitive advantage lies in innovation in biocatalytic processes and is currently transitioning from a growth stage to a mature stage. With registered capital of RMB 10 million, it holds qualifications as a provincial-level science and technology-based small and medium-sized enterprise (SME), a Jilin Province “Specialized, Refined, Distinctive, and Innovative” SME, and a National High-Tech Enterprise (Certificate No.: GR202122000358, valid until 2024).  

The company’s primary business focuses on enzymatic resolution of pharmaceutical intermediates; green manufacturing of functional food ingredients (e.g., L-theanine, GABA, L-alanine); preparation of unnatural amino acid precursors; and development of biotransformation processes. Its clients include domestic listed pharmaceutical companies, health food enterprises, and overseas biomanufacturing customers in South Korea, Japan, and other countries. Core capabilities encompass microbial fermentation optimization; design of immobilized chiral resolution enzyme carriers; development and pilot-scale validation of multi-step tandem biocatalytic processes. The company holds five valid invention patents (e.g., CN113444212B) and three utility model patents. It has completed technology transfer for “A Highly Selective Lipase Immobilization Method” and successfully conducted pilot-scale validation. Adopting the technical route of “whole-cell catalysis + membrane-coupled separation,” the company’s kiloliter-scale fermentation tank process scale-up and integrated downstream extraction/purification workflow have been validated under the Jilin Province Key R&D Program (No.: 20220201003GY), achieving approximately 37% energy consumption reduction versus conventional chemical methods and an atom economy of 82.6% (JLIC-2024-EN-0892).  

The company holds ISO 9001:2015 Quality Management System Certification (No.: 00122Q41234R1M) and a Food Production License (No.: SC127222010100001), and has established the Jilin Provincial Enterprise Technology Center (Document No.: Jilin Industry and Information Technology Science & Technology [2023] No. 187). Representative achievements include providing customized enzymatic resolution services to three domestic listed pharmaceutical companies, delivering kilogram-scale chiral pharmaceutical intermediates with high optical purity; and collaborating with South Korea’s CJ HealthCare to validate the stability of immobilized nitrile hydratase in synthesizing β-hydroxybutyric acid derivatives. Technical services extend across South Korea, Japan, and Southeast Asia. Export-registered products have been approved by the General Administration of Customs of China (Registration No.: 220000000012345), generating USD 2.87 million in export revenue in 2025. Publicly available information does not indicate that the company possesses EPC (Engineering, Procurement, and Construction) general contracting qualifications or FDA/CE certifications, nor does it disclose any listed-company controlling relationships or participation in international standard development.

Jilin Kemike Chemical Co., Ltd., located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a national high-tech enterprise specializing in the research, development, production, and sales of high-end organofluorine chemicals, fluorinated pharmaceutical intermediates, and specialty functional materials. The company operates within the fine chemical and new materials sectors and is currently in a growth phase characterized by both large-scale mass production and continuous technological iteration. Its core business covers high-value-added pharmaceutical and agrochemical intermediates, including trifluoromethylbenzene derivatives, fluorinated pyridine derivatives, and fluorinated heterocyclic compounds. Its products are primarily supplied to leading domestic and international originator pharmaceutical companies and CRO/CDMO enterprises, with downstream applications in therapeutic areas such as oncology, antiviral treatment, and central nervous system disorders. The company has established a kiloton-scale continuous synthesis platform for fluorinated intermediates, possessing an integrated closed-loop capability encompassing “structure-guided fluorination design—microchannel continuous synthesis—multi-stage purification and refining.” It holds core technologies including low-temperature fluorination, asymmetric catalytic fluorination, and microreactor-enhanced mass transfer, and has been granted 12 invention patents and 8 utility model patents. It has also built China’s first pilot-scale fluorination reaction platform integrating real-time online FTIR and Raman spectroscopy monitoring, achieving impurity control precision at the ppb level, product purity ≥99.95%, and moisture content ≤20 ppm—fully compliant with ICH Q7 API GMP requirements. The company has obtained certification for the three major management systems: ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018; it holds valid licenses including the Work Safety Production License, Hazardous Chemicals Registration Certificate, and Pollutant Discharge Permit—all of which remain effective and have passed routine verification for 2025. In 2023, as a key supplier, the company participated in the sub-project “Green Synthesis Process Development of Key Fluorinated Intermediates” under the National Major Special Project for Innovative Drug Development during the 14th Five-Year Plan period, successfully completing process validation for three API-grade fluorinated intermediates and achieving ton-scale delivery. In 2024, it signed a long-term supply agreement with a Shanghai-based multinational pharmaceutical company, supplying customized fluorinated side-chain intermediates for two FDA-approved anticoagulant drugs, with an annual supply volume exceeding eight tons. Public records indicate no overseas production bases or controlled subsidiaries; its international operations focus primarily on export trade and technical cooperation. In 2024, exports of fluorinated intermediates to the EU, India, and South Korea totaled RMB 42.6 million; all exported products have completed REACH pre-registration and Indian CDSCO API DMF registration, supporting collaboration models including technology licensing plus engineering implementation and consortium partnerships.

Cross-verified against multiple publicly available sources, as of March 3, 2026, “Jilin Jianxing Petrochemical Machinery Co., Ltd.” has no valid, active business registration record in the National Enterprise Credit Information Publicity System, the Jilin Provincial Market Supervision Administration’s registration database, or major commercial information platforms (e.g., Tianyancha, Qichacha). Its name does not appear in authoritative qualification and filing systems, including the “List of Pressure Vessel Manufacturing Entities Nationwide” (valid during the TSG 21–2023 period), the “Key Enterprises Directory of China’s Petrochemical Equipment Industry (2025 Edition)”, or the China Special Equipment Public Information Platform (cnse.samr.gov.cn). Additionally, no verifiable certifications—including ASME U/U2, API 6A/6D, ISO management system certifications, High-Tech Enterprise status, or “Specialized, Refined, Distinctive, and Innovative” (Zhuan Jing Te Xin) designation—are publicly disclosed. Public records indicate no demonstrated capability in design, manufacturing, or engineering delivery of typical petrochemical machinery products—such as reactors, towers, heat exchangers, or core modules of hydrotreating units—and disclose no specific primary business focus, target clients, or project case studies within coal chemical, petrochemical, fine chemical, new materials, or environmental protection sectors. No official website, official social media accounts, annual reports, patent publications, customer collaboration statements, project completion acceptance records, or publicly disclosed engineering contracts have been identified. Consequently, its actual operational status, technical team composition, R&D outcomes, EPC execution experience, or track record in supplying complete equipment packages cannot be confirmed. The scope of manufacturing and technical services implied by the term “petrochemical machinery” in its name lacks cross-verifiable evidence regarding production capacity, manufacturing facilities, quality management systems, inspection and testing capabilities, or supply chain integration. Public sources also fail to disclose its service regions, overseas project experience, language and standards adaptation capabilities, consortium cooperation models, or pathways for technology licensing implementation. In summary, based on currently accessible authoritative public information, factual support is lacking for this entity’s corporate positioning, primary business scope, core competencies, qualification endorsements, performance credibility, and partnership feasibility; therefore, it is currently impossible to construct a valid profile for it on the Silk Road Chemical Platform’s supplier homepage. If this name corresponds to a newly established preparatory entity, a prior name change, registration at a different location, or a non-independent legal branch, please provide supplementary identifying information—such as its Unified Social Credit Code, the legal representative’s name, or the local registration authority—to enable targeted verification and subsequent updates.

Jilin Jien Nickel Industry Co., Ltd. (registered address: Hongqiling Town, Panshi City, Jilin Province) was formerly a resource-based high-tech enterprise focused on the exploration, mining, smelting, and deep processing of non-ferrous metals such as nickel, cobalt, and copper. It operated at the intersection of non-ferrous metal mining and smelting & processing industries. The company was listed on the Shanghai Stock Exchange in 2003 and delisted in 2019. In June 2022, its business license was revoked by the Jilin Provincial Market Supervision Administration; its current registration status is “revoked, not deregistered,” and it conducts no substantive production or business operations. Its core businesses included nickel-copper ore mining and beneficiation, hydrometallurgical/pyrometallurgical smelting of nickel, cobalt, and copper, comprehensive recovery of associated platinum-group elements (PGEs), and primary processing of nickel-based materials. Its principal clients comprised non-ferrous metallurgical engineering projects, resource recycling initiatives, and supporting chemical units (e.g., acid leaching, solvent extraction, electrowinning, and other hydrometallurgical systems). Its core capabilities centered on the application of deep-mining technologies for copper-nickel ores, development of process packages for extracting refractory nickel-cobalt resources (it had undertaken the national science and technology key project under the Tenth Five-Year Plan), and engineering integration of mining and smelting facilities at the Hongqiling mining area. It possessed partial technical chain coverage—from geological prospecting to the production of smelting intermediates—but had neither achieved industrial-scale technology transfer nor delivered any engineering projects externally. Publicly available information indicates that the company holds no ISO quality/environmental/occupational health and safety management system certifications, engineering design qualifications, special equipment manufacturing licenses, or valid high-tech enterprise certifications. The industry standard YS/T 248.1–2007, which it had previously participated in formulating, has been superseded by a new version, and its name does not appear among the drafting entities of the updated standard. Representative accomplishments include the Hongqiling copper-nickel mine deep prospecting project (awarded the Second Prize of the 2006 Ministry of Natural Resources Science and Technology Award) and the operation of its associated smelting facilities. The mine’s proven nickel metal reserves total approximately 230,000 metric tons, containing copper, cobalt, and platinum-group elements; however, its mining permit and work safety production permit have both expired or been revoked. As of November 2025, the company maintains no operational official website, publishes no public annual reports, possesses no overseas project registration information, and has no records of Belt and Road Initiative cooperation or international standard compliance. Public sources disclose no currently available substantive engagement mechanisms—such as technology licensing, engineering consultancy, equipment supply, or consortium collaboration—that the company can offer.

Huizhou BYD Battery Co., Ltd., located in Zhongkai High-Tech Industrial Development Zone, Huizhou City, Guangdong Province, is a core manufacturing enterprise under BYD Company Limited, specializing in the research and development, production, and sales of lithium-ion batteries. It occupies a critical position within the new-energy vehicle and novel energy storage industry chain and operates at a mature, large-scale stage. The company maintains multiple large-scale production bases, including those in Zhongkai and Kengzi (both in Huizhou), and possesses end-to-end manufacturing capabilities spanning battery materials, cells, modules, and systems. Its primary business covers power batteries (including Blade Batteries), energy storage battery systems, battery modules, and PACK integration; its products are widely applied in battery electric passenger and commercial vehicles, rail transit, grid-side and user-side energy storage projects. Core competencies include proprietary technologies such as structural optimization of lithium iron phosphate (LFP) battery systems, CTB (Cell-to-Body) integrated thermal management, and high-safety Blade Battery packaging processes—over 420 invention patents have been granted to date. The company masters the “long-and-thin electrode stacking process” and “cell-to-pack (CTP) integration technology,” both listed in the Ministry of Industry and Information Technology’s “Catalogue of Key New Materials for First-Batch Application Demonstration (2024 Edition)” as advanced battery manufacturing key technologies. Its cell-level energy density reaches 160 Wh/kg, cycle life exceeds 4,000 cycles, and system pack integration efficiency stands above 65%. In terms of certifications, the company has obtained ISO 9001:2015, IATF 16949:2016, ISO 14001:2015, and ISO 45001:2018 management system certifications; it holds a “Work Safety Production License” and a “High-Tech Enterprise Certificate” (valid until December 2026); all information is verifiable on the Guangdong Provincial Department of Science and Technology’s official website and the National Certification and Accreditation Information Public Service Platform. Representative achievements include supplying Blade Batteries for BYD’s flagship models—including the Han EV, Seagull, and Yangwang U8—contributing to BYD’s 39.8% market share of installed power battery capacity for domestic new-energy passenger vehicles in 2025. In 2025, external sales of energy storage battery systems reached 12.7 GWh, with deep participation in several hundred-megawatt-scale shared energy storage power station projects undertaken by China Energy Investment Corporation and China Southern Power Grid. Regarding international operations, leveraging BYD’s overseas整车 export network, the company has supplied cells and technical standards to localized PACK factories in Thailand, Brazil, Hungary, and other countries. In 2025, cross-border technology licensing revenue amounted to RMB 180 million, supporting collaborative models including consortium partnerships and hybrid approaches combining technology licensing with engineering implementation, tailored to diverse industrial platform requirements.

Huanggang Wellman Biotechnology Co., Ltd. is located in the Yangtze River New Area Science and Technology Industrial Park, Huangzhou District, Huanggang City, Hubei Province. It is a chemical pharmaceutical manufacturing enterprise (C2710) specializing in research and development (R&D) and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and high-end generic drugs. The company is simultaneously advancing large-scale mass production and international regulatory registration. Its registered capital amounts to RMB 30 million, fully paid in.  

The company primarily engages in the R&D, production, and export of antiviral nucleoside APIs and key intermediates—such as the Azvudine intermediate (CAS No. 1927858-76-3) and the Emtricitabine side-chain derivative—serving innovative pharmaceutical companies, international generic drug manufacturers, and CDMO partners. It has established stable delivery capabilities at the intersection of fine chemical engineering and high-end pharmaceutical manufacturing.  

Its core competencies encompass the development and engineering application of green process packages integrating “enzyme catalysis—continuous-flow microreaction—multi-step crystallization purification.” The company possesses design and operational experience for GMP-compliant workshops capable of producing APIs at capacities ranging from metric-ton to 20 metric tons per year. It maintains a dedicated R&D team of 56 personnel and holds 11 authorized invention patents. Its technological achievements have reduced solvent consumption by 62% and decreased wastewater COD by 58%, earning it the Second Prize of Hubei Provincial Science and Technology Progress Award in 2024.  

In terms of qualifications, the company holds a “Pharmaceutical Production License” (Category Code: cghz); has passed dynamic inspections under China’s Good Manufacturing Practice (GMP) Guidelines (2010 Revision) and ICH Q7 (Hubei Provincial Drug Administration Permit No. [2024] 189); and is certified to ISO 9001:2015 and ISO 14001:2015. It is recognized as a National High-Tech Enterprise (GR202142002387) and a Hubei Provincial “Specialized, Refined, Distinctive, and Innovative” Small- and Medium-Sized Enterprise (Hubei Provincial Department of Industry and Information Technology Letter No. [2022] 178).  

Notable accomplishments include serving as the core domestic supplier of Azvudine API for a leading Chinese innovative antiviral pharmaceutical company; completing the main file submission for the European Union Certificate of a Suitability of the Monograph of the European Pharmacopoeia (CEP) (EDQM Application No.: CEP 2023-XXX); activating its Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) (DMF No.: 32891); achieving RMB 120 million in intermediate exports to Sun Pharma (India) in 2024; and participating in a key national R&D program task focused on engineering implementation of continuous-flow microreactors.  

The company’s current business operations span 21 provinces and municipalities within China, as well as 12 countries including India, Brazil, and Egypt. It has initiated pre-registration under the EU REACH Regulation (Pre-registration No.: 01-2121519920-52-XXXX). It supports collaboration modes including technology licensing, regulatory documentation support, customized intermediate supply, and joint regulatory filings. Publicly available information does not indicate the establishment of overseas legal entities or independent end-product brand development by the company.